Recent Updates
Recently added Catalysts
IRIX Positive Sentiment Score: 70/100

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

Key Takeaway: Iridex Corporation announced its plans to host a third quarter financial results conference call on November 14, 2023, at 2:00 p.m. PT. Additionally, the company will participate in the Stifel Healthcare Conference on November 15, 2023, in New York City. Investors can access the live and recorded webcasts on Iridex's website. This engagement with investors underscores the company's commitment to transparency and communication while emphasizing its innovative ophthalmic products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Announcement of third quarter financial results signifies transparency with investors.
  • Participation in Stifel Healthcare Conference indicates company engagement with the investment community.
  • Use of innovative technology positions Iridex competitively in the ophthalmic market.

Full Press Release Details

MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY.
Third Quarter Earnings Conference Call
The Company’s management team will host a conference to discuss reported financial results and business updates beginning at 2:00 p.m. PT / 5:00 p.m. ET on November 14, 2023.
Stifel 2023 Healthcare Conference
Management is scheduled to present on Wednesday, November 15 at 10:20 a.m. ET.
Investors interested in listening to the conference call and presentation may do so by accessing the live and recorded webcasts on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:

Frequently Asked Questions

When will Iridex announce its third quarter financial results?

Iridex will announce its third quarter financial results on November 14, 2023.

How can I access the earnings conference call?

The conference call can be accessed via the live and recorded webcasts on Iridex's website.

When is Iridex's presentation at the Stifel Healthcare Conference?

Iridex will present at the Stifel Healthcare Conference on November 15, 2023, at 10:20 a.m. ET.

What technology does Iridex use for eye treatments?

Iridex utilizes proprietary MicroPulse® technology for treating sight-threatening eye conditions.

In which markets does Iridex sell its products?

Iridex sells its products in the U.S. and through independent distributors in over 100 countries.

Last updated: Nov 13, 2023